Each subject will receive one infusion of autologous, radiolabeled and BioRBC labeled INTERCEPT RBCs (Test RBCs) and one infusion of autologous BioRBC labeled untreated RBCs (Control RBCs) concomitantly. Each infusion will be approximately 20 mL, i.e., 10 mL of 51-chromium labeled RBC, and 10 mL of